New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
09:16 EDTJPM, IRDM, BSFT, OZM, RAIL, AUXL, SINA, BEAV, OWW, KING, ARIA, TGT, SUNEOn The Fly: Pre-market Movers
HIGHER: Orbitz (OWW), up 9% after Q1 revenue, Q2 revenue outlook top estimates... ARIAD (ARIA), up 3% following upgrade at Jefferies... King Digital (KING), up 2.5% after stock initiated at several firms, including with an Overweight rating at JPMorgan and with a Buy at Deutsche Bank... BE Aerospace (BEAV), up 9% after announcing its plan to explore strategic alternatives to enhance shareholder value... Och-Ziff Capital (OZM), up 2.9% after upgraded at Keefe Bruyette. DOWN AFTER EARNINGS: Auxilium (AUXL), down 5%... FreightCar America (RAIL), down 5.2%... BroadSoft (BSFT), down 16%... Realogy (RLGY), down 6%. ALSO LOWER: Target (TGT), down 1.4% after its CEO Gregg Steinhafel stepped down, effective immediately, and was replaced on an interim basis by CFO John Mulligan.. JPMorgan (JPM), down 3% after reporting in its 10-Q filed with the SEC that it sees Q2 markets revenue down 20% from prior year... SINA (SINA), down 3.2% after downgraded at Oppenheimer... Iridium (IRDM), down 5.6% raising $50M in a direct offering of shares to Baron Funds... SunEdison (SUNE), down 2.8% after Barron's says the company's YieldCo plan could bring scrutiny over taxes.
News For JPM;TGT;ARIA;KING;OWW;BEAV;SINA;AUXL;RAIL;OZM;BSFT;IRDM;SUNE From The Last 14 Days
Check below for free stories on JPM;TGT;ARIA;KING;OWW;BEAV;SINA;AUXL;RAIL;OZM;BSFT;IRDM;SUNE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 15, 2014
09:21 EDTJPMOn The Fly: Pre-market Movers
Subscribe for More Information
08:44 EDTJPMJPMorgan CFO says mortgage production environment remains challenging
JPMorgan CFO Marianne Lake speaking on earnings conference call.
08:41 EDTJPMJPMorgan reports firm NIM down 1 bp, core NIM down 2 bps
JPMorgan reports Q2 firm and core NIM down 1 bp and 2 bps sequentially, to 2.19% and 2.64%, respectively, primarily due to lower loan yields, partially offset by lower long-term debt yields.
08:34 EDTJPMJPMorgan CEO Dimon says feels great, prognosis excellent for condition
Subscribe for More Information
08:30 EDTJPMJPMorgan sees current fixed income and equities environment to persist in Q3
In Fixed Income & Equities, JPMorgan expects the current environment to persist into Q3 with normal seasonal trends. In Securities Services, sees revenue to decrease by approximately $100M in Q3 from $1.14B in Q2, due to seasonality. In Treasury Services, expects revenue to be flat vs. Q2 at approximately $1B in Q3, primarily due to the impact of business simplification and lower trade finance balances and spreads. JPMorgan sees FY14 pretax margin and ROE to be lower than Q2, as the business continues to invest in both infrastructure and controls as well as select front office hiring, but is on track to deliver TTC targets for FY15. Guidance in slides for Q2 earnings conference call.
08:26 EDTJPMJPMorgan expects FY14 adjusted expense $58B+/-
Subscribe for More Information
07:23 EDTJPMFortune to hold a conference
Subscribe for More Information
07:08 EDTJPMJPMorgan CEO says saw encouraging signs toward end of Q2
Subscribe for More Information
07:06 EDTJPMJPMorgan reports Q2 Basel III Common Equity Tier 1 ratio 9.8%
Reports Common Equity Tier 1 of $161B, or ratio of 9.8%. Reports Firm Supplementary Leverage Ratio of 5.4%. Reports "core loans" up 8% compared with the prior year. Consumer & Community Banking: average Consumer & Business Banking deposits up 9%; credit card sales volume up 12%; record client investment assets up 19%; record Business Banking loan originations up 46% Corporate & Investment Bank: maintained #1 ranking for Global Investment Banking fees with 8.2% wallet share YTD; assets under custody up 14%. Commercial Banking: period-end loan balances up 9%, driven by 14% growth in Commercial Real Estate; gross investment banking revenue with Commercial Banking clients up 25%. Asset Management: twenty-first consecutive quarter of positive net long-term client flows; record client assets up 15%; record loan balances up 17%.
07:05 EDTJPMJPMorgan reports headcount down 8,871 to 245,192
Subscribe for More Information
07:04 EDTJPMJPMorgan reports Q2 provision for credit losses $692M
Subscribe for More Information
07:02 EDTJPMJPMorgan says Q2 results include $500M after-tax, or 13c, legal expense
Subscribe for More Information
07:01 EDTJPMJPMorgan reports Q2 adjusted EPS $1.46, consensus $1.29
Subscribe for More Information
06:19 EDTJPMJPMorgan reports June net charge losses 2.84% vs. 3.05% last month
Subscribe for More Information
06:00 EDTSINAStocks with implied volatility movement; KGC SINA
Subscribe for More Information
July 14, 2014
15:24 EDTJPMNotable companies reporting before tomorrow's open
Subscribe for More Information
14:40 EDTJPMJPMorgan July 56.5 straddle priced for 2.2% move into Q2
Subscribe for More Information
11:45 EDTSUNEStocks with call strike movement; BBRY SUNE
Subscribe for More Information
08:01 EDTJPMJP Morgan July volatility increases into Q2 and outlook
Subscribe for More Information
07:37 EDTARIAARIAD announces continuation of Iclusig review under Article 20 procedure
ARIAD Pharmaceuticals announced that the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency has provided the company with a request for limited additional information regarding Iclusig as part of its ongoing review under the Article 20 referral procedure. The PRAC has requested further information regarding proposed dose modifications after achievement of a response and patient monitoring and details concerning a risk management plan. Following ARIAD’s response and input from the agency’s Scientific Advisory Group, the company expects that the PRAC will complete its review and make final recommendations to the Committee for Medicinal Products for Human Use at its meeting in October. As we finalize our recommendations on dose modifications of Iclusig and response monitoring of patients, we will work closely with the European regulatory agency and its expert advisors so that CML patients and their treating physicians have the best guidance available supporting the appropriate use of Iclusig,” said Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. In March ARIAD submitted responses to initial questions outlined by the PRAC as part of the Article 20 process, which was initiated in December of last year, and responses to a second set of questions were submitted to the PRAC in June.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use